This is the first recently reported problem of a medicine shortage in the public sector; previous drug supply disruptions were mainly in private clinics, pharmacies, and hospitals.
Khairy Jamaluddin attributes the drug shortage to the China lockdown, global pharmaceutical supply chain disruption, and an unexpected rise in flu, cough, cold and fever cases.
Dr Koh Kar Chai describes the situation as fluid, with the supply of different medications being disrupted at different times and at various locations.
APHM and PhAMA indicate possible medicine price hikes due to “significant” increases in the cost of logistics, active pharmaceutical ingredients (APIs), and labour.